Composition and process for caring for keratin materials
A composition with Vaccinium, Punica granatum, and Cassia alata extracts addresses glycation in skin proteins, inhibiting AGEs and providing anti-aging benefits.
Patent Information
- Application Number
- PCT/CN2024/090753
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-04-30
- Publication Date
- 2025-11-06
AI Technical Summary
The universal phenomenon of glycation, particularly in the dermal compartment of the skin, leads to irreversible modifications in extracellular matrix proteins, contributing to skin aging, stiffness, and loss of elasticity, and there is a need for products that can inhibit or reduce this process.
A composition comprising extracts of Vaccinium plant, Punica granatum, and Cassia alata is developed to inhibit glycation and provide anti-aging benefits.
The composition effectively inhibits glycation, offering anti-aging effects on keratin materials such as human skin, particularly facial skin, by reducing the formation of advanced glycation end products.
Smart Images

Figure PCTCN2024090753-FTAPPB-I100001 
Figure PCTCN2024090753-FTAPPB-I100002 
Figure PCTCN2024090753-FTAPPB-I100003
Abstract
Description
COMPOSITION AND PROCESS FOR CARING FOR KERATIN MATERIALSTECHNICAL FIELD
[0001] The present invention relates to a composition. In particular, the present invention relates to a composition for caring for keratin materials. The present invention also relates to a non-therapeutic process for caring for keratin materials.BACKGROUND ART
[0002] Glycation is a nonenzymatic process involving a reducing sugar (e.g., glucose or ribose) which reacts according to the Maillard reaction with an amino group of an amino acid residue (such as for example lysine) , particularly an amino acid residue of a protein, to form a Schiffbase. The latter, after a molecular rearrangement called Amadori rearrangement, may lead, through a succession of reactions, to bridging, particularly intramolecular bridging such as for example of the pentosidine type. These reversible reaction products subsequently undergo irreversible oxidation, polymerization, dehydration, and cross-linking reactions to generate advanced glycation end products (AGEs) .
[0003] This phenomenon increases with age. It is characterized by the appearance of glycation products whose content increases with age.
[0004] The glycation of proteins is therefore a universal phenomenon, well known for the skin, particularly for its dermal component, but which also occurs in the annexes thereof such as the nails or the hair, particularly on the keratins and marginally in any protein system ifthe conditions required for glycation exist.
[0005] The human skin consists of two compartments, namely a superficial compartment, the epidermis, and a deep compartment, the dermis.
[0006] The extracellular matrix (ECM) in the dermis is main concern part for glycation. The fibrous ECM proteins are composed of collagens, elastins, fibronectins, and laminins. Molecular modification such as AGEs can remain unrepaired and irreversible. They can be accumulated with age. ECM is closely related to skin aging, moreover the glycation of dermal collagen and elastin fibers contributes to the stiffness and loss of elasticity, forming wrinkles.
[0007] It is very well known that the skin results from a close association between at least two compartments constituting it, namely the epidermis and the dermis. The interactions between the dermis and the epidermis are such that it is reasonable to think that a modification of one can have consequences on the other.
[0008] It can be suspected that the ageing of the dermis in particular with its glycation phenomena, is bound to have consequences on the epidermis which is associated with it. Thus, during skin ageing, the glycation of ECM proteins should result in modifications of the epidermis which necessarily participate in the ageing of the epidermis.
[0009] Therefore, it is desired to have products which reduce or even inhibit the phenomenon of glycation of proteins.SUMMARY OF THE INVENTION
[0010] An object of the present invention is thus to develop a composition for caring for the skin, which can effectively inhibit glycation, and therefore resist skin ageing.
[0011] Another object of the present invention is to provide a non-therapeutic process for caring for the skin.
[0012] Accordingly, in a first aspect, the present invention provides a composition comprising:
[0013] (i) at least one extract of a Vaccinium plant;
[0014] (ii) at least one extract of Punica granatum; and
[0015] (iii) at least one extract of Cassia alata.
[0016] The inventors have now discovered that the composition in the present invention can effectively inhibit glycation.
[0017] In a second aspect, the present invention provides a non-therapeutic process for caring for keratin materials, comprising applying the composition according to the first aspect of the present invention to the keratin materials.
[0018] In a third aspect, the present invention provides a use of the composition according to the first aspect of the present invention for providing anti-aging effect on keratin materials.
[0019] Other subjects and characteristics, aspects and advantages of the present invention will be set forth in the description that follows, and in part, will be obvious from the description, or may be learned by practice of the present invention.DETAILED DESCRIPTION OF THE INVENTION
[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art the present invention belongs to. When the definition of a term in the present description conflicts with the meaning as commonly understood by those skilled in the art the present invention belongs to, the definition described herein shall apply.
[0021] In that which follows and unless otherwise indicated, the limits of a range of values are included within this range, in particular, in the expressions "between... and... " and "ranging from... to... " .
[0022] Moreover, the expression "at least one" used in the present description is equivalent to the expression "one or more" .
[0023] Throughout the instant application, the term “comprising” is to be interpreted as encompassing all specifically mentioned features as well optional, additional, unspecified ones. As used herein, the use of the term “comprising” also discloses the embodiment wherein no features other than the specifically mentioned features are present (i.e., “consisting of” ) .
[0024] Unless otherwise specified, all numerical values expressing amount of ingredients and the like which are used in the description and claims are to be understood as being modified by the term "about" . Accordingly, unless indicated to the contrary, the numerical values and parameters described herein are approximate values which are capable of being changed according to the desired purpose as required.
[0025] For the purposes of the present invention, the term "keratin materials" is intended to cover human skin, mucous membranes such as the lips. Facial skin is most particularly considered according to the present invention.
[0026] All percentages in the present invention refer to weight percentage, unless otherwise specified.
[0027] According to the first aspect, the composition of the present invention comprises:
[0028] (i) at least one extract of a Vaccinium plant;
[0029] (ii) at least one extract of Punica granatum; and
[0030] (iii) at least one extract of Cassia alata.
[0031] Extracts of a Vaccinium plant
[0032] The composition of the present invention comprises at least one extract of a Vaccinium plant.
[0033] The genus Vaccinium comprises more than 450 species, among which there may be mentioned the species Vaccinium myrtillus, Vaccinium angustifollium, Vaccinium arboreum, Vaccinium arctostaphylos, Vaccinium caespitosum, Vaccinium corymbosum, Vaccinium hirsutum, Vaccinium macrocarpum, Vaccinium ovatum, Vaccinium oxycoccos, Vaccinium stamineum, Vaccinium uliginosum, Vaccinium urceolatum and Vaccinium vitis-idaea.
[0034] The extract of a Vaccinium plant may be any extract prepared from any plant material derived from at least one plant of the genus Vaccinium.
[0035] Thus, the extract of a Vaccinium plant used according to the present invention may be obtained from plant material derived from a whole plant or from a plant portion such as the leaves, the stems, the flowers, the petals, the fruit, the roots or dedifferentiated cells.
[0036] Any method of extraction known to a person skilled in the art may be used to prepare the extract contained in the composition according to the present invention.
[0037] There may be mentioned in particular aqueous extracts, alcoholic extracts or extracts using an organic solvent.
[0038] Preferably, the extract of a Vaccinium plant is selected from extracts prepared from material derived from at least one plant selected from Vaccinium myrtillus, Vaccinium angustifollium, Vaccinium arboreum, Vaccinium arctostaphylos, Vaccinium caespitosum, Vaccinium corymbosum, Vaccinium hirsutum, Vaccinium macrocarpum, Vaccinium ovatum, Vaccinium oxycoccos, Vaccinium stamineum, Vaccinium uliginosum, Vaccinium urceolatum and Vaccinium vitis-idaea.
[0039] More preferably, the composition of the present invention comprises an extract of Vaccinium myrtillus.
[0040] Even more preferably, the composition of the present invention comprises a Vaccinium myrtillus fruit extract.
[0041] Advantageously, the extract of a Vaccinium plant is present in the composition of the present invention in an amount ranging from 0.001 wt. %to 30 wt. %, preferably from 0.01 wt. %to 20 wt. %, more preferably from 0.02 wt. %to 10 wt. %, even more preferably from 0.03 wt. %to 5 wt. %, most preferably from 0.05 wt. %to 2 wt. %, relative to the total weight of the composition.
[0042] Extracts of Punica granatum
[0043] The composition of the present invention comprises at least one extract of Punica granatum.
[0044] As used herein, an extract of Punica granatum, also called Punica granatum extract, can be an extract comprising, optionally consisting essentially of material from the fruit-bearing plant species Punica granatum. The extract of Punica granatum is not particularly limited to and may comprise or be any extract or combination of extracts from a Punica granatum suitable for use in the embodiments herein.
[0045] Punica granatum has been reported to contain various bioactive components, including various phytochemicals. Punica granatum may simply be referred to as pomegranate.
[0046] In general, the most abundant phytochemicals in pomegranate juice are polyphenols, including the hydrolyzable tannins called ellagitannins formed when ellagic acid and gallic acid bind with a carbohydrate to form pomegranate ellagitannins, also known as punicalagins. The red color of the juice is attributed to anthocyanins, such as delphinidin, cyanidin, and pelargonidin glycosides. Generally, an increase in juice pigmentation occurs during fruit ripening. Pomegranate peel contains high amount of polyphenols, condensed tannins, catechins, and prodelphinidins. Pomegranate seed oil contains punicic acid, palmitic acid, stearic acid, oleic acid, and linoleic acid.
[0047] Specific examples of Punica granatum extracts are known in art. As such, the Punica granatum extract may be purchased or otherwise obtained commercially from various sources, prepared (e.g., using any conventional extraction technique (s) known in the art) , or combinations thereof.
[0048] In certain embodiments, the extract of Punica granatum is obtained by water extracting (or aqueous extracting) plant material of Punica granatum.
[0049] In further or other embodiments, the extract of Punica granatum is obtained by alcohol extracting (e.g., ethanol extracting) plant material of Punica granatum.
[0050] As will be understood by those skilled in the art, Punica granatum is primarily cultivated for its fruit. As such, in various embodiments, the extract of Punica granatum is an extract of Punica granatum fruit. Suitable extractions include those noted above, e.g., water and ethanol extractions of fruit. The fruit can be from one or more plants, and can be fresh, dried, or otherwise aged.
[0051] The extract of Punica granatum may comprise material from any part of the plant, or combinations of parts, and is not limited to fruit extracts. For example, the extract of Punica granatum may comprise materials extracted from one or more parts of a Punica granatum plant, including the root, stem, bark, rhizome, leaf, bud, flower, seed, and / or fruit thereof. Moreover, such extracts may be further processed (e.g., defatted, partially defatted, ground, dried, precipitated, washed, filtered, mesh-sorted, extracted, distilled, concentrated, etc. ) to obtain the Punica granatum extract. Likewise, the Punica granatum plant may be extracted in raw form or processed prior to extraction of the Punica granatum extract (e.g., used in raw form, suspended form, dehydrated form, concentrated form, etc. ) .
[0052] By way of example, certain extracts can be obtained where Punica granatum (e.g., fruit) is pulverized to a homogeneous size in a mill. Next, the resulting powder is extracted using a water or ethanol solution. The solution is then filtered, and the filtrate can be concentrated under reduced pressure to yield a syrup. The syrup can then be freeze-dried to dryness to obtain extract.
[0053] The Punica granatum extract may be utilized in any form, such as neat (i.e., absent solvents, carrier vehicles, diluents, etc. ) , or disposed in a carrier vehicle, such as a solvent or dispersant. The carrier vehicle, ifpresent, may comprise an aqueous solvent (e.g. water) , an organic solvent, fluid, or oil, or the like, or combinations thereof. When utilized, the carrier vehicle will be selected based on the particular Punica granatum extract utilized.
[0054] Preferably, the composition according to the present invention comprises a Punica granatum fruit extract, i.e., a Punica granatum extract comprising materials obtained (i.e., extracted) from fruit of Punica granatum.
[0055] More preferably, the Punica granatum extract is a Punica granatum fruit extract.
[0056] Advantageously, the extract of Punica granatum is present in the composition of the present invention in an amount ranging from 0.001 wt. %to 10 wt. %, preferably from 0.002 wt. %to 8 wt. %, more preferably from 0.003 wt. %to 5 wt. %, even more preferably from 0.004 wt. %to 3 wt. %, most preferably from 0.005 wt. %to 1 wt. %, relative to the total weight of the composition.
[0057] Extracts of Cassia alata
[0058] The composition of the present invention comprises at least one extract of Cassia alata.
[0059] The extracts to be used in accordance with the present invention may be prepared by known methods of extracting plants or parts thereof. Particulars of suitable conventional extraction processes, such as maceration, remaceration, digestion, agitation maceration, vortex extraction, ultrasonic extraction, countercurrent extraction, percolation, repercolation, evacolation (extraction under reduced pressure) , diacolation and solid / liquid extraction under continuous reflux in a Soxhlet extractor, which are familiar to the expert and which may all be used in principle, can be found, for example, in Hagers Handbuch der pharmazeutischen Praxis (5th Edition, Vol. 2, pp. 1026-1030, Springer Verlag, Berlin-Heidelberg-New York 1991) . Fresh or dried plants or parts thereof are suitable as the starting material although plants and / or plant parts which may be mechanically size-reduced and optionally defatted before extraction are normally used. Any size reduction methods known to the expert, for example comminution with a bladed tool, may be used. The leaves of the plant are particularly preferred for extraction.
[0060] Preferred solvents for the extraction process are organic solvents, water or mixtures of organic solvents and water, more particularly low molecular weight alcohols, esters, ethers, ketones, or halogenated hydrocarbons with more or less large water contents (distilled or non-distilled) , preferably aqueous alcoholic solutions with more or less large water contents. Extraction with water, methanol, ethanol, propanol, butanol, and isomers thereof, acetone, propylene glycols, polyethylene glycols, ethyl acetate, dichloromethane, trichloromethane and mixtures thereof is particularly preferred. The extraction process is generally carried out at 20 to 100℃., preferably at 80 to 100℃. and more particularly at 80 to 90℃. In one possible embodiment, the extraction process is carried out in an inert gas atmosphere to avoid oxidation of the ingredients of the extract. The extraction times are selected by the expert in dependence upon the starting material, the extraction process, the extraction temperature and the ratio of solvent to raw material, etc. After the extraction process, the crude extracts obtained may optionally be subjected to other typical steps, such as for example purification, concentration and / or decoloration. If desired, the extracts thus prepared may be subjected, for example, to the selective removal of individual unwanted ingredients. The extraction process may be carried out to any degree, but is usually continued to exhaustion. Typical yields (=extract dry matter, based on the quantity of raw material used) in the extraction of dried plants or dried plant parts (optionally defatted) are in the range from 10 wt. %to 20 wt. %, preferably 12 wt. %to 19 wt. %and more preferably 13 wt. %to 16 wt. %. If desired, the extracts may then be subjected, for example, to spray drying or freeze drying.
[0061] The extracts according to the present invention have an active substance content in the extracts of 5 wt. %to 100 wt. %, preferably 10 wt. %to 95 wt. %and more preferably 20 wt. %to 80 wt. %. In the context of the present invention, the active substance content is the sum total of all the active substances present in the extract, based on the dry weight of the extract.
[0062] The extract of Cassia alata according to the present invention generally contain substances selected from flavone derivatives, more preferably kaempferol and kaempferol derivatives, tannins, coumarins, anthraquinones, free phenol acids and mixtures thereof, even more preferably p-hydroxybenzoic acid.
[0063] Flavone derivatives in the context of the present invention are understood to be those which can be isolated from the plant Cassia alata. More particularly, they are hydrogenation, oxidation, or substitution products of 2-phenyl-4H-1-benzopyran; hydrogenation may already be present in the 2, 3-position of the carbon chain, oxidation may already be present in the 4-position and substitution products are understood to be the replacement of one or more hydrogen atoms by hydroxy or methoxy groups. Accordingly, this definition also encompasses flavans, flavan-3-ols (catechols) , flavan-3, 4-diols (leucoanthocyanidines) , flavones, flavonols and flavonones in the traditional sense. Particularly preferred flavone derivatives isolated from the plant Cassia alata are kaempferol and kaempferol such as, kaempferol-3-O-sophoroside, kaempferol-7-rhamnoside, kaempferol-3, 7-dirhamnoside.
[0064] Tannins in the context of the present application are tannins which can be isolated from the plant Cassia alata. More particularly, they are polyphenols which may also be referred to as gallotannins by virtue of their derivation from gallic acid. They are mixtures of substances of the pentadigalloyl glucose type. Tannins are also substances formed by oxidative coupling of the galloyl residues in 1, 2, 3, 4, 6-pentagalloyl-D-glucose and derivatives of such substances.
[0065] Coumarins in the context of the present application are understood to be coumarins which can be isolated from the plant Cassia alata. The name coumarin is equivalent to the names cumarin, chromen-2-one, 2H-1-benzopyran-2-one, o-coumaric acid lactone and tonka bean camphor. Coumarin is the cyclization product from coumaric acid. Coumaric acid is ortho-hydroxycinnamic acid. In the context of the present application, coumarin is also understood to include the glucoside of coumaric acid.
[0066] Anthraquinones in the context of the present application are anthraquinones which can be isolated from the plant Cassia alata. More particularly, they are anthraquinone or oxidation or substitution products of 9, 10-anthracene dione, substitution products being understood to be the replacement of one or more hydrogen atoms by hydroxy or methyl groups. The anthraquinones are in particular alizarin, quinizarin, chrysazin, hytsazarin, purpurin, chrysophanic acid, quinalizarin and flavopurpurin.
[0067] In the context of the present application, free phenol acids are understood to be those which can be isolated from the plant Cassia alata, preferably p-hydroxybenzoic acid and o-hydroxybenzoic acid or salicylic acid.
[0068] Preferably, the composition according to the present invention comprise a Cassia alata leaf extract.
[0069] Advantageously, the extract of Cassia alata is present in the composition of the present invention in an amount ranging from 0.001 wt. %to 30 wt. %, preferably from 0.01 wt. %to 20 wt. %, more preferably from 0.02 wt. %to 10 wt. %, even more preferably from 0.03 wt. %to 5 wt. %, most preferably from 0.05 wt. %to 2 wt. %, relative to the total weight of the composition.
[0070] Advantageously, the weight ration of the extract of a Vaccinium plant, the extract of Punica granatum and the extract of Cassia alata in the composition of the present invention is 0.05-5: 1: 0.2-20, preferably 1-5: 1: 1-10, more preferably 2-5: 1: 2-8.
[0071] Aqueous phase
[0072] The composition of the present invention may comprise an aqueous phase.
[0073] Preferably, the aqueous phase comprises water.
[0074] Advantageously, water is present in the composition of the present invention in an amount ranging from 40 wt. %to 99.99 wt. %, preferably from 45 wt. %to 99.99 wt. %, more preferably from 50 wt. %to 99.6 wt. %, relative to the total weight of the composition.
[0075] Optionally, the aqueous phase comprises an organic solvent miscible with water (at room temperature 25℃) selected from monoalcohols, glycols and polyols having from 2 to 20 carbon atoms, such as octyldodecanol, glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, diethylene glycol; and mixtures thereof.
[0076] Advantageously, the aqueous phase is present in the composition of the present invention in an amount ranging from 50 wt. %to 99.99 wt. %, preferably from 55 wt. %to 99.99 wt. %, more preferably from 60 wt. %to 99.6 wt. %, relative to the total weight of the composition.
[0077] Additional cosmetic active ingredients
[0078] The composition of the present invention may comprise an additional cosmetic active ingredient in addition to the cosmetic active ingredients as defined previously.
[0079] The skilled in the art can adjust the type and their amount of the additional cosmetic active ingredients based on the final use of the composition according to the present invention.
[0080] Additional adjuvants or additives
[0081] The composition of the present invention may comprise may also contain conventional cosmetic adjuvants or additives, for instance fragrances, chelating agents, preserving agents and bactericides, surfactants, thickeners, pH regulators, and mixtures thereof.
[0082] The skilled in the art can select the amount of the additional adjuvants or additive so as not to adversely impact the final use of the composition according to the present invention.
[0083] According to a particularly preferred embodiment, the present invention provides a composition comprising, relative to the total weight of the composition:
[0084] (i) from 0.05 wt. %to 2 wt. %of a Vaccinium myrtillus fruit extract;
[0085] (ii) from 0.005 wt. %to 1 wt. %of a Punica granatum fruit extract; and
[0086] (iii) from 0.05 wt. %to 2 wt. %of a Cassia alata leaf extract.
[0087] Galenic form and process
[0088] The composition of the present invention is in the form of emulsion, cream, lotion, or hydrogel, and can be sued as toner, lotion, serum, light cream, nourish cream, sleeping mask, or eye cream.
[0089] The composition of the present invention can be used for caring for keratin materials. In particular, the composition of the present invention can bring benefits on anti-ageing.
[0090] According to the second aspect, the present invention provides a non-therapeutic process for caring for keratin materials, comprising applying the composition according to the first aspect of the present invention to the keratin materials.
[0091] In some embodiments, the present invention provides a non-therapeutic process for anti-aging of keratin materials, comprising applying the composition according to the first aspect of the present invention to the keratin materials.
[0092] In particular, the keratin material is the skin, especially the facial skin.
[0093] In a third aspect, the present invention provides a use of the composition according to the first aspect of the present invention for providing anti-aging effect on keratin materials.
[0094] In particular, the keratin material is the skin, especially the facial skin.
[0095] EXAMPLES
[0096] The examples that follow are given as non-limiting illustrations of the present invention.
[0097] Main raw materials used, trade names and suppliers thereof are listed in Table 1.
[0098] Table 1
[0099] Invention Example 1 and comparative examples 1-6
[0100] Compositions of invention example (IE) 1 and comparative examples (CE) 1-6 were prepared based on the amounts of ingredients given in Table 2. The amounts are given in%by weight of each active ingredient relative to the total weight of the composition.
[0101] Table 2
[0102] Compositions of invention example 1 represents a composition according to the present invention.
[0103] Compositions of comparative examples 1 does not comprise an extract of Punica granatum and an extract of Cassia alata.
[0104] Composition of comparative example 2 does not comprise an extract of a Vaccinium plant and an extract of Cassia alata.
[0105] Composition of comparative example 3 does not comprise an extract of a Vaccinium plant and an extract of Punica granatum.
[0106] Composition of comparative example 4 does not comprise an extract of Cassia alata.
[0107] Composition of comparative example 5 does not comprise an extract of Punica granatum.
[0108] Composition of comparative example 6 does not comprise an extract of a Vaccinium plant.
[0109] Preparation process:
[0110] The compositions listed above were prepared as follows: adding vaccinium myrtillus fruit extract (ifpresents) , Punica granatum fruit extract (ifpresents) , and Cassia alata leaf extract (ifpresents) into a beaker and then adding water with stirring under room temperature to obtain a homogeneous mixture.
[0111] Evaluation
[0112] The effect of compositions prepared above on inhibition of advanced glycation end products was tested as follows.
[0113] A mixed solution containing 80 mg / mL bovine serum albumin and 240 mg / mL glucose was prepared using 0.1mol / L phosphate buffer solution (PBS) , and filtered by 0.22 μm filter membrane, to be used as 2*glycation reaction solution. The compositions according to Table 2 were used as reaction systems. The final concentration of bovine serum albumin and glucose in each reaction system were 40 mg / mL and 120 mg / mL, respectively.
[0114] Table 3. systems for AGEs inhibition test
[0115] The mixtures were well mixed and incubated at 55℃ for 40 hours. PBS or sample solvent were used instead of testing samples as negative control or solvent control, and 1%aminoguanidine hydrochloride was used as positive control, and PBS was used instead of glycation reaction solution as control system. After the reaction, the incubated solution was cooled to room temperature for determination, and 200μL of the reaction solution was added to the 96-well plate in turn, detection was performed by using a fluorescent enzyme spectrometer at the excitation wavelength of 370 nm and the emission wavelength of 440 nm, and the inhibition rate of AGEs was calculated.
[0116] AGE inhibition (%) were calculated according to the following equation:
[0117] wherein
[0118] A-the fluorescence intensity of the glycation system in the testing group;
[0119] B-the fluorescence intensity of PBS in the testing group;
[0120] C-the fluorescence intensity of the glycation system in the control group;
[0121] D-the fluorescence intensity of PBS in the control group.
[0122] The AGE inhibition (%) for each composition of invention example 1 and comparative examples 1-6 were summarized in Table 4.
[0123] Table 4
[0124] It can be seen from Table 4 that composition of invention example 1 shows improved inhibition on glycation as compared with compositions of comparative examples 1-6. Therefore, composition of invention example 1 can be used to provide anti-aging effect on keratin materials.
Claims
1.A composition comprising:(i) at least one extract of a Vaccinium plant;(ii) at least one extract of Punica granatum; and(iii) at least one extract of Cassia alata.2.The composition according to claim 1, wherein the extract of a Vaccinium plant is selected from extracts prepared from material derived from at least one plant selected from Vaccinium myrtillus, Vaccinium angustifollium, Vaccinium arboreum, Vaccinium arctostaphylos, Vaccinium caespitosum, Vaccinium corymbosum, Vaccinium hirsutum, Vaccinium macrocarpum, Vaccinium ovatum, Vaccinium oxycoccos, Vaccinium stamineum, Vaccinium uliginosum, Vaccinium urceolatum and Vaccinium vitis-idaea.3.The composition according to claim 2, wherein the composition comprises an extract of Vaccinium myrtillus, preferably a Vaccinium myrtillus fruit extract.4.The composition according to any of claims 1-3, wherein the extract of a Vaccinium plant is present in an amount ranging from 0.001 wt. %to 30 wt. %, preferably from 0.01 wt. %to 20 wt. %, more preferably from 0.02 wt. %to 10 wt. %, even more preferably from 0.03 wt. %to 5 wt. %, most preferably from 0.05 wt. %to 2 wt. %, relative to the total weight of the composition.5.The composition of any of claims 1-4, wherein the extract of Punica granatum comprises materials extracted from one or more parts of a Punica granatum plant, including the root, stem, bark, rhizome, leaf, bud, flower, seed, and / or fruit thereof.6.The composition of claim 5, wherein the composition comprises a Punica granatum fruit extract.7.Composition of any of claims 1 to 6, wherein the extract of Punica granatum is present in an amount ranging from 0.001 wt. %to 10 wt. %, preferably from 0.002 wt. %to 8 wt. %, more preferably from 0.003 wt. %to 5 wt. %, even more preferably from 0.004 wt. %to 3 wt. %, most preferably from 0.005 wt. %to 1 wt. %, relative to the total weight of the composition.8.Composition of any of claims 1 to 7, wherein the extract of Cassia alata comprises substances selected from the group consisting of flavone derivatives, more preferably kaempferol and kaempferol derivatives, tannins, coumarins, anthraquinones, free phenol acids and mixtures thereof, even more preferably p-hydroxybenzoic acid.9.Composition of any of claims 1 to 8, wherein the composition comprises a Cassia alata leaf extract.10.Composition of any of claims 1 to 9, wherein the extract of Cassia alata is present in an amount ranging from 0.001 wt. %to 30 wt. %, preferably from 0.01 wt. %to 20 wt. %, more preferably from 0.02 wt. %to 10 wt. %, even more preferably from 0.03 wt. %to 5 wt. %, most preferably from 0.05 wt. %to 2 wt. %, relative to the total weight of the composition11.The composition according to claim 1, comprising, relative to the total weight of the composition:(i) from 0.05 wt. %to 2 wt. %of a Vaccinium myrtillus fruit extract;(ii) from 0.005 wt. %to 1 wt. %of a Punica granatum fruit extract; and(iii) from 0.05 wt. %to 2 wt. %of a Cassia alata leaf extract.12.The composition according to any one of claims 1-11, wherein the weight ration of the extract of a Vaccinium plant, the extract of Punica granatum and the extract of Cassia alata in the composition is 0.05-5: 1: 0.2-20, preferably 1-5: 1: 1-10, more preferably 2-5: 1: 2-8.13.The composition according to any one of claims 1-12, further comprising water, preferably in an amount ranging from 40 wt. %to 99.99 wt. %, preferably from 45 wt. %to 99.99 wt. %, more preferably from 50 wt. %to 99.6 wt. %, relative to the total weight of the composition.14.A non-therapeutic process for caring for keratin materials, comprising applying the composition according to any of claims 1 to 13 to the keratin materials.15.A use of the composition according to any of claims 1 to 13 for providing anti-aging effect on keratin materials.
Citation Information
Patent Citations
Beauty composition containing vaccinium vitis-idaea extract and application thereof
CN101543525A
Composition including filamentous bacterium extract and cosmetic method for processing aging sign
CN101926754A
Anti-saccharification agent
CN102058504A
Application of pomegranate extract
CN110652530A
Composition for improving skin elasticity and cosmetic
CN111544324A